Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis

被引:55
作者
Gupta, AK
Lynde, CW
Konnikov, N
机构
[1] Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Med, Div Dermatol, Toronto, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Toronto Gen Hosp, Dept Med, Div Dermatol, Toronto, ON M5G 1L7, Canada
[4] Toronto Western Hosp, Dept Med, Div Dermatol, Toronto, ON M5T 2S8, Canada
[5] Tufts Univ, Sch Med, Dept Dermatol, Boston, MA 02111 USA
关键词
D O I
10.1067/mjd.2001.110644
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objective: Efficacy and safety of sequential pulse therapy with itraconazole and terbinafine were compared with pulse terbinafine alone in the treatment of toenail onychomycosis. Methods: This was a 72-week prospective, single-blind, randomized, multicenter, comparative, parallel group, nonindustry-sponsored trial. A total of 190 patients were recruited from 3 outpatient dermatology offices in North America. Patients were at least 18 years old and had a clinical and mycologic diagnosis of dermatophyte toenail onychomycosis. Patients were randomly assigned to receive sequential pulse therapy (IIT) with 2 pulses of itraconazole followed by 1 or 2 pulses of terbinafine (itraconazole pulse is 200 mg twice daily for 1 week and terbinafine pulse is 250 mg twice daily for 1 week) versus 3 or 4 pulses of terbinafine (TTT). Main outcome measures at week 72 evaluated mycologic cure rate (negative light microscopy and culture), clinical cure (nail appears completely or totally normal), complete cure (clinical and mycologic cure), and effective therapy (mycologic cure and clinical response with at least: 5 mm of new, uninvolved nail growth). Results: At week 72, in the IIT versus TTT groups, the mycologic cure rate was 54 of 75 (72.0%) versus 44 of 90 (48.9%), clinical cure rate was 42 of 75 (56.0%) versus 35 of 90 (38.9%), effective therapy 49 of 75 (65.3%) versus 41 of 90 (45.6%), and complete cure 39 of 75 (52.0%) versus 29 of 90 (32.2%), respectively. Both regimens were well tolerated with no new adverse effects being identified. The rate of permanent discontinuation of therapy because of adverse effects was 2 of 81 (2.5%) with IIT and 2 of 95 (2.1%) with TTT. Each of the adverse effects normalized over time. The number of patients who reported an adverse effect in the 2 groups was 12 of 81 (14.8%) versus 22 of 95 (23.2%), respectively. All these adverse effects were reversible and mild to moderate in severity. Conclusion: Sequential pulse therapy with itraconazole and terbinafine is effective and safe for the treatment of dermatophyte toenail onychomycosis.
引用
收藏
页码:485 / 491
页数:7
相关论文
共 27 条
[1]  
Alpsoy Erkan, 1996, Journal of Dermatology (Tokyo), V23, P259, DOI 10.1111/j.1346-8138.1996.tb04009.x
[2]   Successful therapy of Candida albicans arthritis with a sequential intravenous amphotericin B and oral fluconazole regimen [J].
Barson, WJ ;
Marcon, MJ .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1996, 15 (12) :1119-1122
[3]   PHARMACOKINETIC PROFILE OF ORALLY-ADMINISTERED ITRACONAZOLE IN HUMAN-SKIN [J].
CAUWENBERGH, G ;
DEGREEF, H ;
HEYKANTS, J ;
WOESTENBORGHS, R ;
VANROOY, P ;
HAEVERANS, K .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1988, 18 (02) :263-268
[4]   Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: A double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day [J].
De Backer, M ;
De Vroey, C ;
Lesaffre, E ;
Scheys, I ;
De Keyser, P .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1998, 38 (05) :S57-S63
[5]   Itraconazole pulse therapy for onychomycosis and dermatomycoses: An overview [J].
De Doncker, P ;
Gupta, AK ;
Marynissen, G ;
Stoffels, P ;
Heremans, A .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 37 (06) :969-974
[6]  
DECUYPER C, 1999, CLIN DERMATOL, P119
[7]   Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis [J].
Evans, EGV ;
Sigurgeirsson, B .
BMJ-BRITISH MEDICAL JOURNAL, 1999, 318 (7190) :1031-1035
[8]  
Gupta AK, 1999, J EUR ACAD DERMATOL, V13, P1
[9]   Current management of onychomycosis - An overview [J].
Gupta, AK ;
Scher, RK ;
DeDoncker, P .
DERMATOLOGIC CLINICS, 1997, 15 (01) :121-+
[10]   ANTIFUNGAL AGENTS - AN OVERVIEW .2. [J].
GUPTA, AK ;
SAUDER, DN ;
SHEAR, NH .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1994, 30 (06) :911-933